Cargando…

Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial

BACKGROUND: We aimed to describe the mechanisms of immunological recovery and the effects of blocking CCR5 in patients starting ART with advanced HIV-infection. METHODS: This was a sub-study of a 48 week double-blind, clinical trial where patients starting ART with CD4+ cell counts <100 cells/uL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belaunzarán-Zamudio, Pablo F., Azzoni, Livio, Canaday, David H., Caro-Vega, Yanink N., Clagett, Brian, Rassool, Mohammed S, Rodriguez, Benigno, Sanne, Ian, Sereti, Irini, Sierra-Madero, Juan G., Lederman, Michael M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pathogens and Immunity 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518704/ https://www.ncbi.nlm.nih.gov/pubmed/28736763 http://dx.doi.org/10.20411/pai.v2i2.181

Ejemplares similares

Relationship Between Anemia and Systemic Inflammation in People Living With HIV and Tuberculosis: A Sub-Analysis of the CADIRIS Clinical Trial
por: Araújo-Pereira, Mariana, et al.
Publicado: (2022)

Vitamin D, d-dimer, Interferon γ, and sCD14 Levels are Independently Associated with Immune Reconstitution Inflammatory Syndrome: A Prospective, International Study()
por: Musselwhite, Laura W., et al.
Publicado: (2016)

Country of residence is associated with distinct inflammatory biomarker signatures in HIV-infected patients
por: Manion, Maura, et al.
Publicado: (2017)

Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America
por: Caro-Vega, Yanink, et al.
Publicado: (2018)

96. Human Papilloma Viruses Associated Diseases in a Cohort of Patients with Idiopathic CD4 Lymphopenia
por: Mystakelis, Harry, et al.
Publicado: (2019)

Did Universal Access to ARVT in Mexico Impact Suboptimal Antiretroviral Prescriptions?
por: Caro-Vega, Yanink, et al.
Publicado: (2013)

Temporal changes in ART initiation in adults with high CD4 counts in Latin America: a cohort study
por: Crabtree‐Ramírez, Brenda E, et al.
Publicado: (2019)

Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study
por: Caro-Vega, Yanink, et al.
Publicado: (2022)

2270. Frequency of Syphilis Annual Screening Testing, Prevalence of Infection and Re-infection and Associated Characteristics among People Receiving Care for HIV in an HIV/AIDS Care Clinic in Mexico City (2001–2017)
por: Camiro-Zúñiga, Antonio, et al.
Publicado: (2018)

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
por: Ananworanich, Jintanat, et al.
Publicado: (2015)

Seroepidemiology of SARS-CoV-2 in healthcare personnel working at the largest tertiary COVID-19 referral hospitals in Mexico City
por: Dávila-Conn, Vanessa, et al.
Publicado: (2022)

Paradoxical CD4 Lymphopenia in Autoimmune Lymphoproliferative Syndrome (ALPS)
por: Lisco, Andrea, et al.
Publicado: (2019)

Risk factors associated with prolonged hospital length-of-stay: 18-year retrospective study of hospitalizations in a tertiary healthcare center in Mexico
por: Marfil-Garza, Braulio A., et al.
Publicado: (2018)

Trismus and voice change after starting tuberculosis treatment
por: Rocco, Joseph M., et al.
Publicado: (2021)

Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program
por: Lazzarin, A, et al.
Publicado: (2010)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Monitoring of HIV treatment in seven countries in the WHO Region of the Americas
por: Belaunzarán-Zamudio, Pablo F, et al.
Publicado: (2015)

Frequency of non-communicable diseases in people 50 years of age and older receiving HIV care in Latin America
por: Belaunzaran-Zamudio, Pablo F., et al.
Publicado: (2020)

Corrigendum: Paradoxical CD4 Lymphopenia in Autoimmune Lymphoproliferative Syndrome (ALPS)
por: Lisco, Andrea, et al.
Publicado: (2019)

Lymphopenia, Lymphopenia-Induced Proliferation, and Autoimmunity
por: Sheu, Ting-Ting, et al.
Publicado: (2021)

Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico
por: Belaunzarán-Zamudio, Pablo F., et al.
Publicado: (2017)

Characterization of data-driven geriatric syndrome clusters in older people with HIV: a Mexican multicenter cross-sectional study
por: Hernandez-Ruiz, Virgilio, et al.
Publicado: (2023)

Diagnostic precision of local and World Health Organization definitions of symptomatic COVID-19 cases: an analysis of Mexico's capital
por: Núñez, I., et al.
Publicado: (2022)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
por: López-Huertas, María Rosa, et al.
Publicado: (2020)

Lymphopenia in SARS
por: Panesar, Nirmal S
Publicado: (2003)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4(+) Cell Rises in HIV-Infected Patients
por: Funderburg, Nicholas, et al.
Publicado: (2010)

The HIV epidemic in Latin America: a time to reflect on the history of success and the challenges ahead
por: Crabtree‐Ramírez, Brenda, et al.
Publicado: (2020)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice
por: Reuter, S, et al.
Publicado: (2010)

Lymphopenia and autoimmune diseases
por: Schulze-Koops, Hendrik
Publicado: (2004)

Estimating the Impact of Earlier ART Initiation and Increased Testing Coverage on HIV Transmission among Men Who Have Sex with Men in Mexico using a Mathematical Model
por: Caro-Vega, Yanink, et al.
Publicado: (2015)

Retention in Care, Mortality, Loss-to-Follow-Up, and Viral Suppression among Antiretroviral Treatment-Naïve and Experienced Persons Participating in a Nationally Representative HIV Pre-Treatment Drug Resistance Survey in Mexico
por: Caro-Vega, Yanink, et al.
Publicado: (2021)

Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey
por: De Luca, Andrea, et al.
Publicado: (2019)

CD4 Response Up to 5 Years After Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients in Latin America and the Caribbean
por: Luz, Paula M., et al.
Publicado: (2015)

Immunologic impact of maraviroc in clinical practice of a university hospital
por: Paniagua, S Plata, et al.
Publicado: (2010)

Incidence of ischemic cardiovascular events in the maraviroc clinical development program
por: Portsmouth, S, et al.
Publicado: (2010)

Maraviroc: a review of its use in HIV infection and beyond
por: Woollard, Shawna M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ojvf19uqt8b42541ki1dou3c69